SAT0060

CHOLESTEROL SEQUESTERING IN MACROPHAGES CONTRIBUTES TO THE LIPID PARADOX IN CHRONIC ARTHRITIS

Sandra Pérez-Baos¹, Junko Arakawa², Raquel Largo-Carazo¹, Katsunori Ikewaki², Gabriel Herrero-Beaumont¹. ¹Bone and Joint Research Unit, Rheumatology Dept., IIS-Fundación Jiménez Díaz UAM, Madrid, Spain; ²Division of Anti-aging and Vascular Medicine, Internal Medicine Dept., National Defense Medical College, Tokorozawa, Japan

Background: Patients with active rheumatoid arthritis (RA) have increased cardiovascular mortality, paradoxically associated with reduced circulating lipid levels (1-3). Several disease-modifying antirheumatic drugs (DMARDs), such as the JAK inhibitor tofacitinib, ameliorate disease activity along with an increase in serum lipids (4, 5). We previously demonstrated *in vitro* that tofacitinib favored cholesterol efflux from macrophages through an ABCA1-dependent mechanism (6). Furthermore, tofacitinib-treated chronic arthritic rabbits showed increased circulating lipids and decreased lipid accumulation within the synovium (6).

Objectives: Our aim was to explore *in vivo* whether inflammation impedes cholesterol efflux from macrophages, and whether tofacitinib restores macrophage cholesterol release during chronic arthritis. For that purpose, we assessed the ability of intraperitoneally-injected ³H-cholesterol labelled macrophages to efflux cholesterol to circulating lipoproteins in collagen-induced arthritis (CIA) mice treated with tofacitinib or placebo, as compared to healthy controls.

Methods: DBA/1J mice were randomly assigned to healthy controls (Control, n = 9), CIA (CIA, n = 6) and CIA mice receiving 50 mg/kg/day tofacitinib, orally, for three consecutive days, starting on day 39 after CIA induction and coinciding with disease peak (CIA+TOFA, n = 6). The day after, ³H-cholesterol labeled RAW264.7 macrophages were intraperitoneally injected into mice and tracer appearance was monitored in plasma lipoprotein subfractions, synovium, liver, bile and feces.

Results: The CIA group showed higher C-Reactive protein levels (CRP, µg/ml; Control: 10.90±0.49, CIA: 13.86±1.05, p=0.03 vs. Control) and lower circulating ³H-cholesterol levels (% of injected disintegrations per minute (dpm)/ml; Control: 1.29±0.11, CIA: 0.92±0.11, p=0.04 vs. Control). Both serum CRP and ³H-cholesterol –particularly the HDL fraction– were restored to baseline after the treatment with the JAK inhibitor (CIA +TOFA: 10.97±0.67 µg/ml and 1.37±0.20 % of injected dpm/ml, respectively, p=0.05 vs. CIA). Concomitantly, we observed an upward trend in ³H-cholesterol accumulation within the synovium of CIA animals as compared to controls, which tended to normalize with the treatment.

Conclusion: Systemic inflammation induces cholesterol sequestering within macrophages *in vivo* by acting on cholesterol efflux transporters (6). Tofacitinib favors cholesterol release to plasma lipoproteins, hence increasing circulating cholesterol. This is not only due to a decrease in inflammation –an effect very likely shared with some other biologic DMARDs–, but also to a direct mechanism on ABCA1 transporters that favors cholesterol efflux. To our knowledge, this is the first report suggesting that cholesterol dynamics in the macrophage may contribute to the overall circulating cholesterol levels, especially considering that this phenomenon may occur in other cell types, such as adipocytes.

REFERENCES

- [1] Johnsson H. et al. Ann Rheum Dis. 2013;73:1495–9.
- [2] Myasoedova E. et al. Ann Rheum Dis. 2012;70:482–7.
- [3] Choy E, Sattar N. Ann Rheum Dis. 2009;68:460–9.
- [4] Charles-Schoeman C. et al. Semin Arthritis Rheum. 2016;46:71–80.
- [5] Robertson J. et al. Nat Rev Rheumatol. 2013;9:513–23.
- [6] Pérez-Baos S. et al. Br J Pharmacol. 2017;174:3018–31.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.4318

SAT0061

IMPORTANT ROLE OF CD11C+ CELLS IN INFLAMMATORY ARTHRITIS

Antonia Puchner¹, Elisabeth Simader¹, Victoria Saferding¹, Gerhard Krönke², Rene Pfeifle², Daniel Aletaha¹, Josef S. Smolen¹, Stephan Blüml¹. ¹Medical University Vienna, Internal Medicine III, Vienna, Austria; ²Medical University Erlangen, Erlangen, Germany

Background: Dendritic cells (DCs) are important antigen presenting cells (APCs) and therefore they play an important role in bridging the innate and the adaptive immune response. DCs can be divided in different subsets with specific functions. As powerful APCs, DCs are thought to play an important role in the induction of autoimmune diseases such as

rheumatoid arthritis. However, the active role of DCs in joint inflammation is not known yet.

Objectives: Investigation of the role of DCs cells in joint inflammation and destruction.

Methods: We analyzed histological sections of K/BxN serum transfer arthritis as well as hTNFg arthritis for the presence of CD11c+ cells by immunohistochemistry. We used CD11c-diphtheria toxin receptor (DTR) transgenic mice. K/BxN serum transfer arthritis was induced, and mice were given either DT or PBS or in wt and BARF3 deficient mice. In addition CD11c DTR mice were crossed into hTNFg animals and also received either DT or PBS. The severity of arthritis was determined clinically and histologically.

Results: Both CD8+CD11c+ and CD11b+CD11c+, can be found in synovial tissue in TNF driven arthritis. Upon depletion of CD11c+ cells clinical signs of K/BxN serum transfer arthritis were significantly reduced. Histological analysis found reduced synovial inflammation after the depletion of CD11c+ cells in K/BxN arthritis. In addition, local bone destruction and the number of osteoclasts was also significantly reduced. In addition to K/BxN arthritis, we found that also in TNF-driven arthritis depletion of CD11c+ cells led to a striking reduction of synovial inflammation and a complete depletion of osteoclasts.

Conclusion: These data show that in addition to initiating an adaptive immune response, CD11c+ dendritic cells, are also involved in innate effector mechanisms of inflammatory arthritis. Especially CD11b+CD11c+ and monocyte derived inflammatory seem to play a role in inflammatory arthritis, suggesting that they could be an important therapeutic target.

Disclosure of Interests: Antonia Puchner: None declared, Elisabeth Simader: None declared, Victoria Saferding: None declared, Gerhard Krönke Grant/research support from: Lilly, Pfizer, Speakers bureau: Novartis, Rene Pfeifle: None declared, Daniel Aletaha Grant/research support from: AbbVie, Bristol-Myers Squibb, and MSD, Consultant for: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Medac, Merck, MSD, Pfizer Inc, Roche, and UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Medac, Merck, MSD, Pfizer Inc, Roche, and UCB, Josef S. Smolen Grant/research support from: AbbVie, Eli Lilly, Janssen, MSD, Pfizer, Roche, Consultant for: AbbVie, Amgen, Astra-Zeneca, Celgene Corporation, Celtrion, Eli Lilly, Glaxo, ILTOO, Janssen, MedImmune, MSD, Novartis, Pfizer, Roche, Samsun, Sanofi, UDB, Stephan Blüml: None declared

DOI: 10.1136/annrheumdis-2019-eular.6534

SAT0062

STRATIFIED MEDICINE FOR RHEUMATOID ARTHRITIS: PREDICTING RESPONSE TO BIOLOGIC THERAPY USING IMMUNE CELL SIGNATURES

Gemma Radley¹, Ben Mulhearn^{1,2}, Laura Donlin³, Jennifer H. Anolik⁴, Michael Brenner⁵, Soumya Raychaudhuri^{1,5}, Kimme Hyrich⁶, Ann Morgan⁷, Gerry Wilson⁸, John Isaacs⁹, Tracy Hussell², Anne Barton¹, Sebastian Viatte¹.

¹University of Manchester, Arthritis Research UK Centre for Genetics and Genomics, Manchester, United Kingdom; ²University of Manchester, Manchester Collaborative Centre for Inflammation Research, Manchester, United Kingdom; ³Weill Cornell Medical College, Department of Medicine, New York, NY, United States of America; ⁴University of Rochester, Department of Medicine, Rochester, NY, United States of America; ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States of America; ⁶University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom; ⁷Chapel Allerton Hospital, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom; ⁸University College Dublin, Conway Institute of Biomolecular and Biomedical Research, Dublin, Ireland; ⁹Newcastle-upon-Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle-upon-Tyne, United Kingdom

Background: Treatment selection of biologic therapy for patients with rheumatoid arthritis (RA) is currently a trial and error process, with approximately 40% failing to respond well to the first biologic. The lack of biomarkers to predict treatment response leads to further pain, joint damage, patient anxiety and is cost ineffective for those who are non-responders.

Objectives: We aim to identify immune signatures from a pre-treatment blood test to inform the choice of treatment strategies for stratified medicine.

Methods: RA patients with active disease (DAS28 > 5.1) who failed to respond to conventional DMARDs and were due to commence biologic treatment were included in the BRAGGS cohort. Peripheral blood mononuclear cells (PBMCs) taken before the initiation of biologic treatment were available for 300 patients (good (60%), moderate (25%), and non-